The company's lead compound, Aramchol, is being studied as a potential treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis (NASH). NASH is a chronic liver disease with limited treatment options. Galmed's therapy aims to modify the disease and reduce the risk of severe liver complications such as cirrhosis and carcinoma. In addition to liver-related risks, NASH is also associated with an increased risk of cardiovascular complications. Galmed is currently conducting a Phase 3 registrational study for Aramchol and is also collaborating on the development of a synthetic peptide for liver diseases. The company is headquartered in Tel Aviv, Israel.